Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model.
The leading cause of morbidity and mortality in severe burn wound patients is infection. Treatment of burn wound infection is complicated by the emergence of antibiotic resistant organisms. A potential therapeutic alternative to antibiotic drugs is the local administration of polyclonal antibodies, termed passive local immunotherapy (PLI), directly to the burned tissue. A mouse burn wound infection model to simulate full thickness burn wound infection was used to evaluate the efficacy of passive local immunotherapy as a viable prophylactic or therapeutic agent. Pooled human immunoglobulins (IgG), delivered locally to the site of infection, are shown to be more effective at preventing fatal burn wound sepsis than treatment by intravenous infusion of IgG. A single 10 mg dose of human IgG administered locally to the burned, infected tissue site, either 24 hours prior to bacterial challenge, or within 3 hours after bacterial challenge, enhanced animal survival significantly (P < 0.001 and P < 0.05 respectively) compared to control animals. In addition, reduced levels of bacteria were found in local and systemic tissues of IgG-treated mice compared to control mice (P < 0.05). These data support the local use of polyclonal immunoglobulin preparations as an efficacious and cost effective means to prevent and treat burn wound infections.
Felts
A G
AG
Anthony G. Gristina Institute for Biomedical Research, USA.
Giridhar
G
G
Grainger
D W
DW
Slunt
J B
JB
D000818:Animals; D002056:Burns / Q000150:complications*; D005260:Female; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D051379:Mice; D011552:Pseudomonas Infections / Q000382:microbiology / Q000401:mortality / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000254:growth & development; D015996:Survival Rate; D014946:Wound Infection / Q000382:microbiology / Q000628:therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous